BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – The refrigeration technology has come a long way to meet the requirements in the medical and healthcare industry.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas to construct a high-resolution molecular landscape of pancreatic cancer.

A recent study reveals differences in how symptom toxicity is reported for children receiving cancer treatment in clinical trials.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration informing us that they have extended the review timeline for the New Drug Application for omaveloxolone for the treatment of Friedreich’s ataxia by three months.

NanoViricides, Inc. provides further details on its rapid drug development strategy for Monkeypox virus.

Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2022 financial results.

Novaliq, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol® (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED).

Fusion Pharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2022 and provided an update on clinical and corporate developments.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 353 owned and operated outpatient imaging centers, reported financial results for its second quarter of 2022.

Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.